Vet Med - Czech, 2001, 46(9):257-274 | DOI: 10.17221/7883-VETMED

Quinolones: a class of antimicrobial agentsReview

G. Sárközy
Department of Pharmacology and Toxicology, Faculty of Veterinary Science, Szent István University, Budapest, Hungary

The fluoroquinolones are a series of synthetic antibacterial agents that are used in the treatment of a variety of bacterial infections. These agents inhibit the DNA gyrase, abolishing its activity by interfering with the DNA-rejoining reaction. The inhibition of the resealing leads to the liberation of fragments that are subsequently destroyed by the bacterial exonucleases. All fluoroquinolones accumulate within bacteria very rapidly, so that a steady-state intrabacterial concentration is obtained within a few minutes. Resistance develops slowly and is usually chromosomal and not plasmid mediated. However, development of resistance and transfer between animal and human pathogens has become a fervently argued issue among the microbiologists. Another concern regarding the use of new quinolones in the veterinary field is a possible detrimental effect on the environment. It still seems unlikely that the controlled use of veterinary quinolones will give rise to unfavorable effects on the environment.

Keywords: fluoroquinolones; chemistry; pharmacokinetics; resistance; therapeutical use

Published: September 30, 2001  Show citation

ACS AIP APA ASA Harvard Chicago IEEE ISO690 MLA NLM Turabian Vancouver
Sárközy G. Quinolones: a class of antimicrobial agents. Vet Med-Czech. 2001;46(9-10):257-274. doi: 10.17221/7883-VETMED.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Abadía A.R., Aramayona J.J., Fraile L., Martinez C., Garcia M.A., Bregante M.A. (1994a): Pharmacokinetics of enrofloxacin and ciprofloxacin during ontogeny in the rabbit. In: Proceedings of the Sixth Congress of the European Association for Veterinary Pharmacology and Toxicology. Edinburgh, Scotland. 231.
    2. Abadía A.R., Aramayona J.J., Muñoz M.J., Pla Delfina J.M., Saez M.P., Bregante M.A. (1994b): Disposition of ciprofloxacin following intravenous administration in dogs. J. Vet. Pharmacol. Therap., 17, 384-388. Go to original source... Go to PubMed...
    3. Akahane K., Segiguchi M., Une T., Osoda Y. (1989): Structure-epileptogenicity relationship of quinolones with special reference their interaction with γ-amino-butiric acid receptor sites. Antimicrob. Agents Chemother., 33, 1704-1708. Go to original source... Go to PubMed...
    4. Althreuther P. (1987): Data on chemistry and toxicology of Baytril. Vet. Med. Rev., 2, 87-89.
    5. Anadón A., Martínez-Larrañaga M.R., Díaz M.J., Fernández R., Martínez M.A., Fernández-Cruz M.L., Fernández M.C. (1994): Pharmacokinetic properties of norfloxacin in pigs. In: Proceedings of the Sixth Congress of the European Associassion for Veterinary Pharmacology and Toxicology. Edinburgh, Scotland. 230-231.
    6. Anadón A., Martínez-Larrañaga M.R., Díaz M.J., Bringas P., Martínez M.A., Fernández-Cruz M.L., Fernández M.C., Fernández R. (1995): Pharmacokinetics and residues of enrofloxacin in chickens. Am. J. Vet. Res., 56, 501-506.
    7. Apley M.D., Upson D.W. (1993a): Regional danafloxacin lung tissue concentrationsand their relationship to regional pulmonary blood flow in consolidated and nonconsolidated bovine lung. Am. J. Vet. Res., 54, 944-951.
    8. Apley M.D., Upson D.W. (1993b): Lung tissue concentrations and plasma pharmacokinetics of danofloxacin in calves with acute pneumonia. Am. J. Vet. Res., 54, 937-943.
    9. Aramayona J.J., Garcia M.A., Fraile L.J., Abadfa A.R., Bregante M.A. (1994): Placental transfer of enrofloxacin and ciprofloxacin in rabbits. Am. J. Vet. Res., 55, 1313- 1318.
    10. Ashby J., Piddock L.J.V., Vise R. (1985): Correspondence: An investigation of the hydrophobicity of the quinolones. J. Antimicrob. Chemother., 16, 805-808. Go to original source... Go to PubMed...
    11. Ball P. (1986): Ciprofloxacin: an overview of adverse experiments. J. Antimicrob.Chemother., 18 (suppl. D), 187-193. Go to original source... Go to PubMed...
    12. Barza M. (1991): Use of quinolones for treatment of ear and eye infections. Eur. J. Clin. Microbiol. Infect. Dis., 10, 296-303. Go to original source... Go to PubMed...
    13. Bates S.A., Elder M.G. (1988): An evaluation of pelvic tissue concentrations after oral administration of enoxacin. J. Antimicrob. Chemother., 21 (Suppl. B), 79-85. Go to original source... Go to PubMed...
    14. Bayer A.S., Hirano L., Yih J. (1988): Development of β-lactam resistance and increased quinolone MICs during therapy of experimental Pseudomonas aeruginosa endocarditis. Antimicrob. Agents Chemother., 32, 231-235. Go to original source... Go to PubMed...
    15. Beam T.R. jr. (1994): Fluoroquinolones in Animal Feeds. Am. Soc. Microbiol. News, 60, 348-349.
    16. Berg J. (1988): Clinical indications for enrofloxacin in domestic animals and poultry. In: Quinolones: A new class of antimicrobial agents for use in veterinary medicine. In: Proc. West Vet. Conf, Las Vegas, Nevada: Mobay Corporation.
    17. Bhaumik A. (1997): Effect of norfloxacin treatment in acute enteritis in dogs. Indian Vet. J., 74, 246-247.
    18. Blaser J., Stone B.B., Groner M.C., Zinner S.H. (1987): Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob. Agents Chemother., 31, 1054-1060. Go to original source... Go to PubMed...
    19. Blaser J., Lüthy R. (1988): Comparative study on antagonistic effects of low pH and cation supplementation on in-vitro activity of quinolones and aminoglycosides against Pseudomonas aeruginosa. J. Antimicrob. Chemother., 22, 15-22. Go to original source... Go to PubMed...
    20. Bowles S.K., Popovski Z., Rybak M.J., Beckman H.B., Edwards D.J. (1988): Effects of norfloxacin on theophylline pharmacokinetics in steady-state. Antimicrob. Agents Chemother., 32, 510-513. Go to original source... Go to PubMed...
    21. Braunius W.W. (1987): Effect van Baytril™ (Bay Vp 2674) op jonge kalkoenen lijdende aan luchtweginfecties. Tijdschr. Diergeneeskd, 112, 531-533. Go to PubMed...
    22. Bregante M.A., Abadía A.R., Mora J., Aramayona J.J., Garcia M.A., Fraile L. (1994): Milk transfer of enrofloxacin and ciprofloxacin in the rabbit. In: Proceedings of the Sixth Congress of the European Associassion for Veterinary Pharmacology and Toxicology. Edinburgh, Scotland. 231-232.
    23. Brown S.A., Cooper J., Gauze J.J., Greco D.S., Weise D.W., Buck J.M. (1990): Pharmacokinetics of norfloxacin in dogs after a single intravenous and single and multiple oral administrations of the drug. Am. J. Vet. Res., 51, 1065-1070.
    24. Brumfitt W., Franklin I., Grady D., Hamilton-Miller J.M.T., Iliffe A. (1984): Changes in the pharmacokinetics of ciprofloxacin and fecal flora during administration of a 7-day course to human volunteers. Antimicrob. Agents Chemother., 26, 757-761. Go to original source... Go to PubMed...
    25. Carlier M.B., Scorneaux B., Zenebergh A., Desnottes J.F., Tulkens P.M. (1990): Cellular uptake, localization and activity of fluoroquinolones in uninfected and infected macrophages. J. Antimicrob. Chemother., 26 (Suppl. B), 27-39. Go to original source... Go to PubMed...
    26. Chamberland S., Bayer A.S., Schollaardt T., Wong S.A., Bryan L.E. (1989): Characterization of mechanism of quinolone resistance in Pseudomonas aeruginosa strains isolated in vitro and in vivo during experimental endocarditis. Antimicrob. Agents Chemother., 33, 624-634. Go to original source... Go to PubMed...
    27. Chang T., Black A., Dunkey A., Wolf R., Sedman A., Latts J., Welling P.G. (1988): Pharmacokinetics of intravenous and oral enoxacin in healthy volunteers. J. Antimicrob. Chemother., 21 (Suppl. B.), 49-56. Go to original source... Go to PubMed...
    28. Chapman J.S., Georgopapadakou N.H. (1988): Routes of quinolone permeation in E. coli. Antimicrob. Agents Chemother., 32, 438-442. Go to original source... Go to PubMed...
    29. Chen Z., Fung K.F., Fang B., Song Y. (1994): Antimicrobial and pharmacokinetic studies of fluoroquinolones in chickens. In: Proceedings of the Sixth Congress of the European Associassion for Veterinary Pharmacology and Toxicology. Edinburgh, Scotland. 209-210.
    30. Chu D., Fernandez P., Claiborne A., Shen L., Pernet A. (1988): Structure-activity relationships in quinolone antimicrobials: design, synthesis and biological activities of novel isothiazoquinolones. Drugs Exp. Clin. Res., 14, 379-383.
    31. Cooper A.D., Fuller J.R., Fuller M.K., Whitlestone P., Wise, D.R. (1993): In vitro activity of danofloxacin, tylosin and oxytetracycline against mycoplasmas of veterinary importance. Res. Vet. Sci., 54, 329-334. Go to original source... Go to PubMed...
    32. Cutarelli P.E., Laso J.H., Lazarus H.M., Putnam S.P., Jacobs M.R. (1991): Topical fluoroquinolones: antimicrobial activity and in vitro corneal epithelial toxicity. Curr. Eye Res., 10, 557-563. Go to original source... Go to PubMed...
    33. Dalhoff A., Weidner W. (1984): Diffusion of ciprofloxacin into prostatic fluid. Eur. J. Clin. Microbiol., 3, 360-362. Go to original source... Go to PubMed...
    34. Darouiche R., Perkins B., Musher D., Hamill R., Tsai S. (1990): Levels of rifampin and ciprofloxacin in nasal secretions: correlation with MIC90 and eradication of nasopharyngeal carriage of bacteria. J. Inf. Dis., 162, 1124-1127. Go to original source... Go to PubMed...
    35. Desgrandchamps D. (1989): Increasing rates of in vitro resistance to ciprofloxacin and norfloxacin in isolates from urine specimens. Antimicrob. Agents Chemother., 33, 595-596. Go to original source... Go to PubMed...
    36. Desnottes J.F., Diallo N., Moret G., Santonja R. (1987): Effects of subinhibitory concentrations of pefloxacin on the adherence of Staphylococcus aureus to human cells. Drugs Exp. Clin. Res., 13, 69-73.
    37. Dijkstra J.W., McConville M.L., Nouws J.F.M. (1994): Effects of srafloxacin hydrochloride on human enteric bacteria under simulated human gut conditions. In: Proceedings of the Sixth Congress of the European Association for Veterinary Pharmacology and Toxicology, Edinburgh, Scotland. 75.
    38. Diver J.M., Wise R. (1986): Morphological and biochemical changes in Escherichia coli after exposure to ciprofloxacin. J. Antimicrob. Chemother., 18 (suppl. D), 31-41. Go to original source... Go to PubMed...
    39. Dobbs B.R., Gazeley L.R., Stewart I.A., Edwards I.R. (1988): Pharmacokinetics and sputum concentrations of enoxacin after twice daily oral dosing for seven days. J. Antimicrob. Chemother., 21 (Suppl. B), 61-66. Go to original source... Go to PubMed...
    40. Dorfman M., Barsanti J., Budsberg S. (1995): Enrofloxacin concentrations in dogs with the normal prostate and dogs with chronic bacterial prostatitis. Am. J. Vet. Res., 56, 386-390.
    41. Dowling P.M., Wilson R.C., Tyler J.W., Duran S.H. (1995): Pharmacokinetics of ciprofloxacin in ponies. J. Vet. Pharmacol. Therap., 18, 7-12. Go to original source... Go to PubMed...
    42. Drusano G.L., Plaisance K.I., Forrest A., Standiford H.C. (1986): Dose ranging study and constant infusion evaluation of ciprofloxacin. Antimicrob. Agents Chemother., 30, 440-443. Go to original source... Go to PubMed...
    43. Drusano G.L., Johnson D.E., Rosen M., Standiford H. C. (1993): Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas spesis. Antimicrob. Agents Chemother., 37, 483-490. Go to original source... Go to PubMed...
    44. Duval J.M., Budsberg S.C. (1995): Cortical bone concentrations of enrofloxacin in dogs. Am. J. Vet. Res., 56, 188-192.
    45. Endtz H.P., Rujis G.J., Van Klingeren B., Jansen W.H., Van der Reyden T., Mouton R. P. (1991): Quinolone resistance in campylobacter isolated from manand poultry following the introduction of fluoroquinolones in veterinary medicine. J. Antimicrob. Chemother., 27, 199-208. Go to original source... Go to PubMed...
    46. Felmingham D., Foxal P., O'Hare M.D., Webb G., Ghosh G., Grüneberg R.N. (1988): Resistance studies with ofloxacin. J. Antimicrob. Chemother., 22 (Suppl. C), 27-34. Go to original source... Go to PubMed...
    47. Fernandes P.B. (1988): Mode of action, and in vitro and in vivo activities of the fluoroquinolones. J. Clin. Pharmacol., 28, 156-168. Go to original source... Go to PubMed...
    48. Fitzgeorge R., Featherstone A., Baskerville A. (1988): The effect of ofloxacin on the intracellular growth of Legionella pneumophila in guinea pig alveolar phagocytes. J. Antimicrob. Agents Chemother., 22 (Suppl. S), 53-57. Go to original source... Go to PubMed...
    49. Foerster D. (1987): Visualization of the bactericidal action of Baytril by microphotography. Vet. Med. Rev., 2, 100-103.
    50. Forrest A., Nix D.E., Ballow C.H., Goss T.F., Birmingham M.C., Schentag J.J. (1993): Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob. Agents Chemother., 37, 1073-1081. Go to original source... Go to PubMed...
    51. Friis C. (1991): Danofloxacin in calves: pharmacokinetics and penetration into the respiratory tract tissue, Acta Vet. Scand., (Suppl.), 87, 104-106.
    52. Friis C. (1994): Penetration of danofloxacin into respiratory tract tissues and secretions in pigs. In: Proceedings of the Sixth Congress of the European Associassion for Veterinary Pharmacology and Toxicology. Edinburgh, Scotland. 208-209.
    53. Frost R.W., Carlson J.D., Dietz A.J.,Jr., Heyd A., Lettieri J.T. (1989a): Ciprofloxacin pharmacokinetics after a standard or high-fat/high-calcium breakfast. J. Clin. Pharmacol., 29, 953-955. Go to original source... Go to PubMed...
    54. Frost R.W., Lettieri J.T., Krol G., Shamblen E.C., Lasseter K.C. (1989b): The effects of cirrhosis on the steady-state pharmacokinetics of oral ciprofloxacin. Clin. Pharmacol. Therap., 45, 608-616. Go to original source... Go to PubMed...
    55. Furet Y.X., Pechére J.C. (1991): Newly documented antimicrobial activity of quinolones. Eur. J. Clin. Microbiol. Infect. Dis., 10, 249-254. Go to original source... Go to PubMed...
    56. Gasser T., Graversen P., Madsen P. (1987): Treatment of complicated urinary tract infections with ciprofloxacin. Am. J. Med., 82 (Suppl. 4A), 278-281.
    57. Giamarellou H., Kolokythas E., Petrikkos G., Gazis J., Aravantino D., Sfikakis P. (1989): Pharmacokinetics of three newer quinolones in pregnant and lactating women. Am. J. Med., 87 (Suppl. 5A), 49-51. Go to original source... Go to PubMed...
    58. Giles C.J., Magonigle R.A., Grimshaw W.T.R., Tanner A.C., Risk J.E., Lynch M.J., Rice J.R. (1991): Clinical pharmacokinetics of parenterally administered danofloxacin in cattle. J. Vet. Pharmacol. Therap., 14, 400-410. Go to original source... Go to PubMed...
    59. Giles C.J., Grimshaw W.T.R., Shanks D.J. et al. (1991): The efficacy of danofloxacin in the therapy of acute bacterial pneumonia in housed beef cattle. Vet. Rec., 128, 296-300. Go to original source... Go to PubMed...
    60. Goodman L.S., Gilman A. (1992): The Pharmacological Basis of Therapeutics. 8th ed. New York, Macmillan. 1057.
    61. Gootz T.D., McGuirk P.R., Moynihon M.S., Haskell S.L. (1994): Placement of alkyl substituents on the C7 piperazine ring of fluoroquinolones: Dramatic differential effects on mammalian topoisomerase II and DNA gyrase. Antimicrob. Agents Chemother., 38, 130-133. Go to original source... Go to PubMed...
    62. Gould I.M., Milne K., Jason C. (1990): Concentration-dependent bacterial killing, adaptive resistance and post-antibiotic effect of ciprofloxacin alone and in combination with gentamycin. Drugs Exp. Clin. Res., 26, 621-628.
    63. Grasela T.J.Jr., Schentag J.J., Sedman A.J., Wilton J.H., Thomas D.J., Schultz R.W., Lebsack M.E., Kinkel A.W. (1989): Inhibition of enoxacin absorption by antacids or ranitidine. Antimicrob. Agents Chemother., 33, 615-617. Go to original source... Go to PubMed...
    64. Greenwood D., Baxter S., Cowlishaw A., Eley A., Slater G.J. (1984): Antibacterial activity of ciprofloxacin in conventional tests and in a model of bacterial cystitis. Eur. J. Clin. Microbiol., 3, 351-354. Go to original source... Go to PubMed...
    65. Grimshaw W.T.R., Magonigle R.A., Giles C.J., Tanner A.C., Risk J.E., Lynch M.J., Rice J.R. (1990a): The pharmacokinetics of danofloxacin in cattle. In: XVI World Buiatrics Congress, Salvador, Bahia, Brazil.
    66. Grimshaw W.T.R., Giles C.J., Cooper A.C. et al. (1990b): The efficacy of danofloxacin in the therapy of pneumonia associated with Pasteurella species in housed calves. Dtsch. Tierarztl. Wschr., 97, 529-532.
    67. Gulkarov A., Ziv G. (1994): Some pharmacokinetic features of norfloxacin nicotinate in turkeys. In: Proceedings of the Sixth Congress of the European Association for Veterinary Pharmacology and Toxicology. Edinburgh, Scotland. 235.
    68. Gyrd-Hansen N., Nielsen P. (1994): The influence of feed on the oral bioavailability of enrofloxacin, oxytetracycline, penicillin V and spiramycin in pigs. In: Proceedings of the Sixth Congress of the European Associassion for Veterinary Pharmacology and Toxicology. Edinburgh, Scotland. 242-243.
    69. Harder S., Staib A.H., Beer C., Papenburg A., Stille W., Shah P.M. (1988): 4-Quinolones inhibit biotransformation of caffeine. Eur. J. Clin. Pharmacol., 35, 651-656. Go to original source... Go to PubMed...
    70. Hayem G., Petit P.X., LeVacher M., Gaudin C., Kahr M.F., Pocidalo J.J. (1994): Cytofluorometric analysis of chondrotoxicity of fluoroquinolone antimicrobial agents. Antimicrob. Agents Chemother., 38, 243-247. Go to original source... Go to PubMed...
    71. Hinz K.H., Rottmann S. (1990): Studies in vivo on the efficacy of enrofloxacin against Mycoplasma gallisepticum. Avian Pathol., 19, 511-522. Go to original source... Go to PubMed...
    72. Höffler D., Dalhoff A., Gau W., Beerman D., Michael A. (1984): Dose- and sex independent disposition of ciprofloxacin. Eur. J. Clin. Microbiol., 3, 363-366. Go to original source... Go to PubMed...
    73. Hoogkamp-Korstanje J.A.A. (1984): Comparative in vitro activity of five quinolone derivates and five other antimicrobial agents used in oral therapy. Eur. J. Clin. Microbiol., 3, 333-338. Go to original source... Go to PubMed...
    74. Hooper D., Wolfson J. (1985): The fluoroquinolones: Structures, mechanisms of action and resistance and spectra of activity in vitro. Antimicrob. Agents Chemother., 28, 581- 586. Go to original source... Go to PubMed...
    75. Hooper D.C., Wolfson J.S. (1991): Mode of action of the new quinolones: new data. Eur. J. Clin. Microbiol. Inf. Dis., 10, 223-231. Go to original source... Go to PubMed...
    76. Jackson J.A., Davidson J.N., Ter Hune T.N., Magonigle R.A. (1990): A dose response study of the fluoroquinolone, danofloxacin, against induced bovine pneumonic pasteurellosis. In: XVI World Buiatrics Congress, Salvador, Bahia, Brazil.
    77. Janin N., Meugnier H., Desnottes J.F., Woehrle R., Fleurette J. (1987): Recovery of pefloxacin in saliva and feces and its action on oral and fecal floras of healthy volunteers. Antimicrob. Agents Chemother., 31, 1665-1668. Go to original source... Go to PubMed...
    78. Jenkins W., Friedlander L. (1988): The pharmacology of the quinolone antibacterial agents. In: Quinolones: A new class of antimicrobial agents for use in veterinary medicine. Proc. West Vet. Conf, Las Vegas, Nevada: Mobay Corporation Animals Health Division, Shawnee, Kansas. 5-16.
    79. Jordan F.T.W., Horrocks B.K., Jones S.K., Cooper A.C., Giles C.J. (1993): A comparison of the efficacy of danofloxacin and tylosin in the control of Mycoplasma gallisepticum infection in broiler chicks. J. Vet. Pharmacol. Toxicol., 16, 79-86. Go to original source... Go to PubMed...
    80. Kaatz G.W., Seo S.M., Ruble C.A. (1991): Mechanisms of fluoroquinolone resistance of Staphylococcus aureus. J. Infect. Dis., 163, 1080-1086. Go to original source... Go to PubMed...
    81. Kato M., Onedara T. (1988): Effect of ofloxacin on the uptake of (3H) thymidine by articular cartilage cells in rat. Toxicol. Lett., 44, 131-142. Go to original source... Go to PubMed...
    82. Kempf I., Gesbert F., Guittet M., Bennejean G. (1992): Efficacy of danofloxacin in the therapy of experimental mycoplasmosis in chicks. Res.. Vet. Sci., 53, 257-259. Go to original source... Go to PubMed...
    83. Kotera Y., Watanabe M., Yoshida S., Inoue M., Mitsuhashi S. (1991): Factors influencing the uptake of norfloxacin by Escherichia coli. J. Antimicrob. Chemother., 27, 733-739. Go to original source... Go to PubMed...
    84. Kresken M., Wiedemann B. (1988): Development of resistance to nalidic acid and the fluoroquinolones after the introduction of norfloxacin and ofloxacin. Antimicrob. Agents Chemother., 32, 1285-1288. Go to original source... Go to PubMed...
    85. Küng K., Riond J.L., Wolffram S., Wanner M. (1993): Comparison of an HPLC and bioassay method to determine antimicrobial concentrations after intravenous and oral administration of enrofloxacin in four dogs. Res. Vet. Sci., 54, 247-248. Go to original source... Go to PubMed...
    86. Lavy E., Ziv G., Glickman A. (1994): Pharmacokinetics of norfloxacin in the donkey (Equus asinus). In: Proceedings of the Sixth Congress of the European Association for Veterinary Pharmacology and Toxicology. Edinburgh, Scotland. 52-53.
    87. Lekeux P., Art T. (1988): Effect of enrofloxacin therapy on shipping fever pneumonia in feedlot cattle. Vet. Rec., 123, 205-207. Go to original source... Go to PubMed...
    88. Lode H., Höffken G., Prinzig C., Glatzel P., Wiley R., Olschewski P., Sievers B., Reimnitz D., Borner K., Koeppe P. (1987): Comparative pharmacokinetics of new quinolones. Drugs, 34 (Suppl. 1), 21-25. Go to original source... Go to PubMed...
    89. Lode H., Höffken G., Boeckk M., Deppermann N., Borner K., Koeppe P. (1990): Quinolone pharmacokinetics and metabolism. J. Antimicrob. Chemother., 26 (Suppl. B4), 1-9. Go to original source... Go to PubMed...
    90. Ludwig E., Székely É., Csiba A., Graber H. (1988): The effect of ciprofloxacin on antipyrine metabolism. J. Antimicrob. Chemother., 22, 61-67. Go to original source... Go to PubMed...
    91. Maesen F.P.V., Davies B.I., Geraeds W.H., Baur C. (1987): The use of quinolones in respiratory tract infections. Drugs, 34 (Suppl 1), 74-79. Go to original source... Go to PubMed...
    92. Malmborg A.S., Rannikko S. (1988): Enoxacin distribution in human tissues after multiple oral administration. J. Antimicrob. Chemother., 21 (Suppl. B), 57-60. Go to original source... Go to PubMed...
    93. Martínez-Larrañaga M.R., Díaz M.J., Bringas P., Fernández M.D., Fernández-Cruz M.L., Martínez M.A., Anadón A. (1994): Bioavalability and residues of enrofloxacin and its metabolite ciprofloxacin in broiler chickens. In: Proceedings of the Sixth Congress of the European Association for Veterinary Pharmacology and Toxicology. Edinburgh, Scotland. 238-239.
    94. McQueen C., Williams G. (1987): Effects of quinolone antibiotics in tests for genotoxicity. Am. J. Med., 82 (Suppl. 4A), 94-96.
    95. Mevius D.J., Breukink H.J., Guelen P.J.M., Jansen T., De Gréve B. (1990): Pharmacokinetics, metabolism and renal clearance of flumequine in veal calves. J. Vet. Pharmacol. Therap., 13, 159-169. Go to original source... Go to PubMed...
    96. Montay G., Goueffon Y., Roquet F. (1984): Absorption, distribution, metabolic fate and elimination of pefloxacin mesylate in mice, rats, dogs, monkeys and humans. Antimicrob. Agents Chemother., 25, 463-472. Go to original source... Go to PubMed...
    97. Neer T.M. (1988): Clinical pharmacologic features of fluoroquinolone antimicrobial drugs. J. Am. Vet. Med. Assoc., 193, 577-580. Go to PubMed...
    98. Neu H.C. (1988): Quinolones: A new class of antimicrobial agents with wide potential uses. Med. Clin. North Am., 72, 623-636. Go to original source... Go to PubMed...
    99. Neu H.C. (1991): Synergy and antagonism of combinations with quinolones. Eur. J. Clin. Microbiol. Infect. Dis., 10, 255-261. Go to original source... Go to PubMed...
    100. Neu H.C., Kumada T., Chin N.X., Mandell W. (1987): The post-antimicrobial suppressive effect of quinolone agents. Drugs Exp. Clin. Res., 13, 63-67.
    101. Nikaido H., Thanassi D.G. (1993): Minireview: Penetration of lipophilic agents with multiple protonation sites into bacterial cells: Tetracyclines and fluoroquinolones as examples. Antimicrob. Agents Chemother., 37, 1393-1399. Go to original source... Go to PubMed...
    102. Nix D.E., Schentag J.J. (1988): The quinolones: an overview and comparative appraisal of their pharmacokinetics and pharmacodynamics. J. Clin. Pharmacol., 28, 169- 178. Go to original source... Go to PubMed...
    103. Nix D.E., Watson W.A., Lener M.E., Frost R..W., Krol G., Goldstein H., Lettieri J., Schentag J.J. (1989): Effects of aluminium and magnesium antacids and ranitidine on the absorption of ciprofloxacin. Clin. Pharmacol. Therap., 46, 700-705. Go to original source... Go to PubMed...
    104. Norrby S.R. (1991): Side effects of quinolones: Comparisons between quinolones and other antibiotics. Eur. J. Clin. Microbiol. Infect. Dis., 10, 378-383. Go to original source... Go to PubMed...
    105. Novotny M.J., Shaw D.H. (1991): Effect of enrofloxacin on digoxin clearance and steady-state serum concentrations in dogs. Can. J. Vet. Res., 55, 113-116.
    106. Okazaki O., Kurata T., Tachizawa H. (1988): Effect of new quinolones on drugmetabolizing enzyme system of rat hepatic microsomes. Chemotherapy, 34, 149-154. Go to original source... Go to PubMed...
    107. Oomori Y., Yasue T., Aoyma H., Hirai K., Suzue S., Yokota T. (1988): Effects of fleroxacin on HeLa cell functions and topoisomerase II. J. Antimicrob. Chemother., 22 (Suppl. D), 91-97. Go to original source... Go to PubMed...
    108. Parpia S., Nix D., Hejmanowski H., Wilton J., Schentag J. (1989): Sucralfate reduces the gastrointetinal absorption of norfloxacin. Antimicrob. Agents Chemother., 33, 99- 102. Go to original source... Go to PubMed...
    109. Patil V.K., Keskar D.V., Jagadish S., Bhalerao D.P., Sharma L.K. (1995): Clinicopathology of urinary tract infections in dogs. Indian Vet. J., 72, 374-377.
    110. Pérez-Trallero E., Urbieta M., Jimenez D., Garcia-Arenzana J.M., Cilla G. (1993): Ten-year survey of quinolone resistance in Escherichia coli causing urinary tract infections. Eur. J. Clin. Microbiol. Infect. Dis., 12, 349-351. Go to original source... Go to PubMed...
    111. Piddock L.J. (1994): New quinolones and Gram-positive bacteria. Antimicrob. Agents Chemother., 38, 163-169. Go to original source... Go to PubMed...
    112. Piddock L.J.V., Wise R. (1989): Mechanism of resistance to quinolones and clinical perspectives. J. Antimicrob. Chemo-ther., 23, 475-483. Go to original source... Go to PubMed...
    113. Pijpers A., Vernooy J.C.M., Cruijsen A.L.M., Van Leengoed L.A.M.G., Koeman J., Hessels A.H., Vandenhoek J., Verheijden J.H.M. (1994): Efficacy of parenteral treatment with oxytetracycline and enrofloxacin against Actinobacillus pleuropneumoniae in swine. In: Proceedings of the Sixth Congress of the European Association for Veterinary Pharmacology and Toxicology. Edinburgh, Scotland. 93.
    114. Preheim L., Cuevas T., Roccaforte J., Mellencamp M., Bittner M. (1987): Oral ciprofloxacin in the treatment of elderly patients with complicated urinary tract infections due to trimethoprim/sulfamethoxazole-resistant bacteria. Am. J. Med., 82 (Suppl. 4A), 295-297.
    115. Prescott J.F., Yielding K.M. (1990): In vitro susceptibility of selected veterinary bacterial pathogens to ciprofloxacin, enrofloxacin and norfloxacin. Can. J. Vet. Res., 54, 195-197.
    116. Pyörälä S., Panu S., Kaartinen L. (1994): Single-dose pharmacokinetics of enrofloxacin in horses. In: Proceedings of the Sixth Congress of the European Association for Veterinary Pharmacology and Toxicology, Edinburgh, Scotland. 45-46.
    117. Ramon J., Dautrey S., Farinoti R., Carbón C., Rubenstein E. (1994): Intestinal elimination of ciprofloxacin in rabbits. Antimicrob. Agents Chemother., 38, 757-760. Go to original source... Go to PubMed...
    118. Richez P., Dellac B., Froyman R. (1994): Pharmacokinetics of enrofloxacin in pigs after single and repeated in-feed medication with Baytril 2.5%. In: Proceedings of the Sixth Congress of the European Association for Veterinary Pharmacology and Toxicology. Edinburgh, Scotland. 207-208.
    119. Ridgway G.L., Mumtaz G., Gabriel F.G., Oriel J.D. (1984): The activity of ciprofloxacin and other 4-quinolones against Chlamydia trachomatis and Mycoplasmas in vitro. Eur. J. Clin. Microbiol., 3, 344-346. Go to original source... Go to PubMed...
    120. Rowan R.C., Mullenix T.A., Arroyo J.C., Voris J.C. (1988): Development of Pseudomonas aeruginosa resistance to norfloxacin during therapy. Drug Intellig. Clin. Pharm., 22, 773-776. Go to original source... Go to PubMed...
    121. Rybak M.J., Bowles S.K., Chandrasekar P.H., Edwards D.J. (1987): Increased theophylline concentration secondary to ciprofloxacin. Drug Intellig. Clin. Pharm., 21, 879-881. Go to original source... Go to PubMed...
    122. Semjén G., Blaskó É. (1994): In vitro emergence of resistance of flumequine and enrofloxacin in strains of Staphylococcus aureus. In: Proceedings of the Sixth Congress of the European Association for Veterinary Pharmacology and Toxicology, Edinburgh, Scotland. 239-240.
    123. Sheer M. (1987): Concentrations of active ingredient in the serum and in tissues after oral and parenteral administration of Baytril. Vet. Med. Rev., 2, 104-118.
    124. Smith J.T. (1984): Mutational resistance to 4-quinolone antibacterial agents. Eur. J. Clin. Microbiol., 3, 347-350. Go to original source... Go to PubMed...
    125. Smith J.T. (1986): The mode of action of 4-quinolones and possible mechanisms of resistance. J. Antimicrob. Chemo-ther., 18 (suppl. D), 21-29. Go to original source... Go to PubMed...
    126. Soback S., Gips M., Bialer M. (1994a): Norfloxacin nicotinate pharmacokinetics in unweaned and weaned calves. In: Proceedings of the Sixth Congress of the European Association for Veterinary Pharmacology and Toxicology, Edinburgh, Scotland. 63-64.
    127. Soback S., Gips M., Bialer M., Bor A. (1994b): Effect of lactation on single-dose pharmacokinetics of norfloxacin nicotinate in ewes. Antimicrob. Agents Chemother., 38, 2336-2339. Go to original source... Go to PubMed...
    128. Sorgel F., Seelman R., Naber K., Metz R., Muth P. (1988): Metabolism of fleroxacin in man. J. Antimicrob. Agents Chemother., 22 (Suppl. D), 169-178. Go to original source... Go to PubMed...
    129. Sorgel F., Jaehde U., Naber K., Stephan U. (1989): Pharmacokinetic disposition of fluoroquinolones in human body fluids and tissues. Clin. Pharmacokin., 16 (Suppl. 1), 5- 24. Go to original source... Go to PubMed...
    130. Studdert V.P., Hughes K.L. (1992): Treatment of opportunistic mycobacterial infections with enrofloxacin in cats. J. Am. Vet. Med. Assoc., 201, 1388-1390. Go to PubMed...
    131. Sullivan M.C., Cooper B.W., Nightingale C.H., Quintiliani R., Lawlor M.T. (1993): Evaluation of the efficacy of cipro-floxacin against Streptococcus pneumoniae by using a mouse protection model. Antimicrob. Agents Chemother., 37, 234-239. Go to original source... Go to PubMed...
    132. Swanson R.N., Hardy D.J., Chu D.T.W., Shipkowitz N.L., Clement J.J. (1991): Activity of temafloxacin against respiratory pathogens. Antimicrob. Agents Chemother., 35, 423-429. Go to original source... Go to PubMed...
    133. Takács-Novák K., Noszal B., Hermecz I., Keresztúri G., Podányi B., Szász G. (1990): Protonation equilibria of quinolone antibacterials. J. Pharm. Sci., 79, 1023-1028. Go to original source... Go to PubMed...
    134. Takayama S., Watanabe T., Akiyama Y. et al. (1986): Reproductive toxicity of ofloxacin. Arzneimittelforschung, 36, 1244-1248. Go to PubMed...
    135. Thomas V., Deleforge J., Bolsramé B. (1994a): Pharmacokinetics of marbofloxacin in preruminant and ruminant cattle. In: Proceedings of the Sixth Congress of the European Association for Veterinary Pharmacology and Toxicology, Edinburgh, Scotland. 60-61.
    136. Thomas V., Deleforge J., Bolsramé B., Espinasse J. (1994b): Pharmacokinetics of marboflaxicin in healthy and sick pre-ruminant calves. In: Proceedings of the Sixth Congress of the European Association for Veterinary Pharmacology and Toxicology, Edinburgh, Scotland. 61.
    137. Thoung-Guyot M., Domarle O., Pacidalo J.J., Hayem G. (1994): Effects of fluoroquinolones on cultured articular chondrocytes flow cytometric analysis of free radical production. J. Pharmacol. Exp. Therap., 271, 1544-1549.
    138. VanCutsem P.M., Babish J.G., Schwark W.S. (1990): The fluoroquinolone antimicrobials: Structure, antimicrobial activity, pharmacokinetics, clinical use in domestic animals and toxicity. Cornell Vet., 80, 173-186. Go to PubMed...
    139. Venezia R.A., Prymas L.A., Shayegani A., Yocum D.M. (1989): In vitro activities of amifloxacin and two of its metabolites. Antimicrob. Agents. Chemother., 33, 762-766. Go to original source... Go to PubMed...
    140. Voight W.H. (1987): Electron microscopic studies on the effect of a quinolone carboxylic acid derivative on the ultrastructure of Escherichia coli and staphylococcal bacteria in vitro. Vet. Med. Rev., 2, 119-121.
    141. Walker R.D., Stein G.E., Budsberg S.C., Rosser E.J.Jr., MacDonald K.H. (1989): Serum and tissue fluid norfloxacin concentrations after oral administration of the drug to healthy dogs. Am. J. Vet. Res., 50, 154-157.
    142. Walker R.D., Stein G.E., Hauptman J.G., MacDonald K.H., Budsberg S.C., Rosser E.J.Jr. (1990): Serum and tissue cage fluid concentrations of ciprofloxacin after oral administration of the drug to healthy dogs. Am. J. Vet. Res., 51, 896-900.
    143. Walker R.D., Stein G.E., Hauptman J.G., McDonald K.H. (1992): Pharmacokinetic evaluation of enrofloxacin administered orally to healthy dogs. Am. J. Vet. Res., 53, 2315-2319.
    144. Watanabe M., Kotera Y., Yosue K., Inoue M., Mitsuhashi S. (1990): In vitro emergence of quinolone-resistant mutants of E. coli, Enterobacter cloaceae and Serratia marcescens. Antimicrob. Agents. Chemother., 34, 173-175. Go to original source... Go to PubMed...
    145. Wolfson J.S., Hooper D.C. (1991): Pharmacokinetics of quinolones: newer aspects. Eur. J. Clin. Microbiol. Infect. Dis., 10, 267-274. Go to original source... Go to PubMed...
    146. Yamamoto T., Watanabe K., Horikita T. et al. (1992): Therapeutic efficacy of enrofloxacin to swine Actinobacillus pleuropneumoniae infection. Kachiku Shinryo, 352, 19- 27.
    147. Zweerink M.M., Edison A.M. (1988): The uptake of 3H-norfloxacin by human polymorphonuclear leukocytes. J. Antimicrob. Chemother., 21, 266-267. Go to original source... Go to PubMed...

    This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY NC 4.0), which permits non-comercial use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content